Are all subtypes created equal? the effectiveness of antiretroviral therapy against non-subtype B HIV-1

Clinical Infectious Diseases

Volumn 48, Issue 9, 2009, Pages 1306-1309

  Kosakovsky Pond, Sergei L ^a   Smith, Davey M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

CODON; DRUG EFFICACY; GENETIC CODE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MICROBIAL DIVERSITY; NONHUMAN; NOTE; PHYLOGENY; PRIORITY JOURNAL; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; CLASSIFICATION; DRUG EFFECT; GENETICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; TREATMENT OUTCOME; UNITED STATES;

EID: 65549168625     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598503     Document Type: Note

References (38)

1. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
2. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34.
3. Geretti AM, Harrison L, Green H, et al. The effect of HIV-1 subtype on virological and im- munological response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48:1296-1305 (in this issue).
4. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-23.
5. Clavel F, Guetard D, Brun-Vezinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:343-6.
6. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpan- demic HIV-1. Science 2006;313:523-6.
7. Van Heuverswyn F, Li Y, Neel C, et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006; 444:164.
8. Perrin L, Kaiser L, Yerly S. Travel and the spread ofHIV-1 genetic variants. Lancet Infect Dis 2003;3:22-7.
9. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. Science 2000;288:55-6.
10. HIV sequence database. July 2007. Available at: http://www.hiv.lanl.gov. Accessed 21 January 2009.
11. McCutchan FE, Hoelscher M, Tovanabutra S, et al. In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection. J Virol 2005;79:11693-704.
12. Harris ME, Serwadda D, Sewankambo N, et al. Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate 1. AIDS Res Hum Retroviruses 2002; 18:1281-90.
13. Peeters M. Recombinant HIV sequences: their role in the global epidemic. Available at: http://www.hiv.lanl.gov/content/index. Accessed 21 January 2009.
14. Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 1998;67: 1-25.
15. Gao F, Morrison SG, Robertson DL, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. JVirol 1996;70:1651-67.
16. Zeldovich KB, Chen P, Shakhnovich EI. Protein stability imposes limits on organism complexity and speed of molecular evolution. Proc Natl Acad Sci USA 2007; 104:16152-7.
17. Rhodes T, Wargo H, Hu WS. High rates of human immunodeficiency virus type 1 recombination: near-random segregation ofmarkers one kilobase apart in one round of viral replication. J Virol 2003; 77:11193-200.
18. Brumme ZL, Brumme CJ, Carlson J, et al. Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cy- totoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J Virol 2008;82:9216-27.
19. Frost SD, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005; 102:18514-9.
20. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296:1439-43.
21. Poon AF, Kosakovsky Pond SL, Bennett P, Richman DD, Leigh Brown AJ, Frost SD. Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis C virus. PLoS Pathog 2007; 3:e45.
22. Thomson MM, Najera R. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev 2005;7: 210-24.
23. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19:1-7.
24. Finzi D. Identification of a reservoir for HIV- 1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
25. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma vire- mia. Science 1997;278:1291-5.
26. Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-1. J Clin Virol 2004;29: 152-9.
27. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31:298-303.
28. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24: 1449-54.
29. Sylla M, Chamberland A, Boileau C, et al. Characterization of drug resistance in antiret-roviral-treated patients infected with HIV-1 CRF02-AG and AGK subtypes in Mali and Burkina Faso. Antivir Ther 2008; 13:141-8.
30. Nyombi BM, Holm-Hansen C, Kristiansen KI, Bjune G, Muller F. Prevalence of reverse tran- scriptase and protease mutations associated with antiretroviral drug resistance among drug-naive HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania. AIDS Res Ther 2008; 5:13.
31. Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008;10: 212-23.
32. Kantor R, Katzenstein DA, Efron B, et al. Impact ofHIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005;2:e112.
33. Little SJ, Holte S, Routy JP, et al. Antiretro-viral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
34. Smith DM, Schooley RT. Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis 2008; 46:1598-600.
35. Liu L, MayS, Richman DD, etal. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS 2008;22: 835-9.
36. Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. The emergence of HIV/AIDS in the Americas and beyond. Proc Natl Acad Sci U S A 2007; 104:18566-70.
37. King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008;22:1709-17.
38. Holguin A, Lopez M, Soriano V. Reliability of rapid subtyping tools compared to that of phylogenetic analysis for characterization of human immunodeficiency virus type 1 non- B subtypes and recombinant forms. J Clin Microbiol 2008; 46:3896-9.